-+ 0.00%
-+ 0.00%
-+ 0.00%

TG THERAPEUTICS INC - TOP-LINE DATA FROM PHASE 3 SUBCUTANEOUS BRIUMVI TRIAL EXPECTED YEAR-END 2026 OR Q1 2027

Reuters·04/15/2026 11:30:00

Please log in to view news